Avian Vaccine production cell line鸭胚胎干细胞-疫苗生产用细胞-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

Avian Vaccine production cell line鸭胚胎干细胞-疫苗生产用细胞株

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

www.biovector.net

描述：

雄性绿头鸭胚胎干细胞，广泛用于疫苗生产

Cellline name    Avian Vaccine production cell line鸭胚胎干细胞

Comments          Group: Bird cell line.

Group:Vaccine production cell line.

Speciesof origin         Anas platyrhynchos(Mallard) (Anas boschas)

Breed/subspecies:GL30.

Sex of cell:  Male

Category:   Embryonic stem cell

Publications      

PubMed=20562528

OlivierS., Jacoby M., Brillon C., Bouletreau S., Mollet T., Nerriere O., Angel A.,Danet S., Souttou B., Guehenneux F., Gauthier L., Berthome M., Vie H.,Beltraminelli N., Mehtali M.

Avian Vaccine production cell line鸭胚胎干细胞, a duck embryonic stem cell-derived substrate for the industrialproduction of therapeutic monoclonal antibodies with enhanced ADCC activity.

MAbs2:405-415(2010)

Description:

The Avian Vaccine production cell line鸭胚胎干细胞 is a proprietary embryonic stem cell-based technology for theproduction of a wide variety of human and veterinary viral and therapeuticvaccines.

It canbe used for the manufacturing of inactivated viruses, live attenuated viruses,live vectors, and subunit vaccines.

Today,more than 20 different families of viruses have been shown to efficientlypropagate in EB66 cells and more than 60 human and veterinary EB66-basedvaccines are currently being developed utilizing the technology in R&D andclinical phases.

The first veterinary vaccine produced in EB66 cells obtained licensure inSeptember 2012 and the H5N1 adjuvanted pandemic Influenza vaccine produced bythe Chemo-Sero-Therapeutic Research Institute (Kaketsuken) in collaborationwith GSK is currently in a New Drug application (NDA)-Phase in Japan.